Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier

Androgen deprivation therapy (ADT) has been the standard of care for the last 75 years in metastatic hormone sensitive prostate cancer (PCa). However, this approach is rarely curative. Recent clinical trials have demonstrated that ADT combined with other agents, notably docetaxel and abiraterone, le...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Asian J Urol
Autores principales: Etheridge, Tyler, Damodaran, Shivashankar, Schultz, Adam, Richards, Kyle A., Gawdzik, Joseph, Yang, Bing, Cryns, Vincent, Jarrard, David F.
Formato: Artigo
Lenguaje:Inglês
Publicado: Second Military Medical University 2019
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363606/
https://ncbi.nlm.nih.gov/pubmed/30775249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2018.09.001
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares